Pfizer Publish New Analysis Showing Long Term Therapy Slowed Progression of Rare Neurodegenerative Disease

Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the

Continue Reading

Pfizer Acquires Baxter’s Vaccines for $635m

Pfizer yesterday announced that they have agreed to purchase two of Baxter International’s commercially marketed vaccines and part of Baxter’s production facilities for $635 million. The purchase will give Pfizer access to Baxter’s meningitis C jab NeisVac-C and FSME-IMMUN/TicoVac, a vaccine that helps protect against tick-borne encephalitis – an infection of the brain transmitted by

Continue Reading

Pfizer Announce Positive Preliminary Phase III Clinical Results

Pfizer yesterday announced positive results from their phase III clinical trial comparing prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly, with on-demand treatment for moderately severe to severe hemophilia B. Top-line results showed that the clinical trial met its primary endpoint, with a statistically noteworthy reduction in the annualised bleeding rate in

Continue Reading

Positive Results for Pfizer’s Lung Cancer Therapy, Xalkori

click Xalkori” src=”http://i61.tinypic.com/kng1x.jpg” width=”204″ height=”126″ />Pfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy. Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared

Continue Reading

Positive Clinical Study Results for Pfizer’s Chantix

Pfizer announced yesterday that Chantix/Champix (varenicline) has been shown to help smokers unable to quit ‘cold turkey’ kick their habit by slowly reducing the amount of cigarettes they smoke. The initial clinical study to assess the drug demonstrated that Chantix/Champix helped improve abstinence rates, in people wanting to reduce smoking prior to quitting.

Continue Reading